Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Quest Diagnostics    DGX


News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Studies from Quest Diagnostics Yield New Information about Chronic Lymphocytic Leukemia

share with twitter share with LinkedIn share with facebook
share via e-mail
01/31/2019 | 05:00pm EDT

By a News Reporter-Staff News Editor at Cancer Weekly -- Data detailed on Oncology - Chronic Lymphocytic Leukemia have been presented. According to news reporting originating from Marlborough, Massachusetts, by NewsRx correspondents, research stated, "The prognostic role of cytogenetic analysis is well-established in B-cell chronic lymphocytic leukemia (CLL). Approximately 80% of patients have a cytogenetic aberration."

Our news editors obtained a quote from the research from Quest Diagnostics, "Interphase FISH panels have been the gold standard for cytogenetic evaluation, but conventional cytogenetics allows detection of additional abnormalities, including translocations, complex karyotypes and multiple clones. Whole genome copy number assessment, currently performed by chromosomal microarray analysis (CMA), is particularly relevant in CLL for the following reasons: (1) copy number alterations (CNAs) represent key events with biologic and prognostic significance; (2) DNA from fresh samples is generally available; and (3) the tumor burden tends to be relatively high in peripheral blood. CMA also identifies novel copy number variants and copy-neutral loss-of-heterozygosity (CN-LOH), and can refine deletion breakpoints. The Cancer Genomics Consortium (CGC) Working Group for CLL has performed an extensive literature review to describe the evidence-based clinical utility of CMA in CLL."

According to the news editors, the research concluded: "We provide suggestions for the integration of CMA into clinical use and list recurrent copy number alterations, regions of CN-LOH and mutated genes to aid in interpretation."

For more information on this research see: Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia. Cancer Genetics, 2018;228-229():236-250. Cancer Genetics can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Cancer Genetics - www.journals.elsevier.com/cancer-genetics/)

The news editors report that additional information may be obtained by contacting P.M. Miron, Quest Diagnost, Marlborough, MA 01752, United States. Additional authors for this research include G.D. Wenger, A. Chaubey, D.P. Dash, R. Kanagal-Shamanna, S. Kantarci, R. Kolhe, D.L. Van Dyke, L. Wang, D.J. Wolff and K. Chun (see also Oncology - Chronic Lymphocytic Leukemia).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.cancergen.2018.07.004. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Copyright 2019, NewsRx LLC, source Health Newsletters

Stocks mentioned in the article
ChangeLast1st jan.
CANCER GENETICS INC 0.74% 0.2445 Delayed Quote.1.03%
QUEST DIAGNOSTICS 0.06% 85.75 Delayed Quote.2.92%
share with twitter share with LinkedIn share with facebook
share via e-mail
04/18QUEST DIAGNOSTICS : Launches New Consumer-Initiated STD Tests Through QuestDirec..
04/16QUEST DIAGNOSTICS INC : quaterly earnings release
04/11QUEST DIAGNOSTICS : Workforce Drug Testing Positivity Climbs to Highest Rate Sin..
04/05QUEST DIAGNOSTICS : Ex-dividend day for
04/04QUEST DIAGNOSTICS : To Release First Quarter 2019 Financial Results On April 23
04/03QUEST DIAGNOSTICS : Presents Supplier Excellence Awards to Four Partners
04/01QUEST DIAGNOSTICS INC : Change in Directors or Principal Officers (form 8-K)
04/01QUEST DIAGNOSTICS : Achieves Perfect Score On 2019 Human Rights Campaign Corpora..
04/01QUEST DIAGNOSTICS : Massachusetts Governor Baker Visits State of the Art Quest D..
03/26QUEST DIAGNOSTICS : to Present New Insights from Genetic Testing at the 2019 Ann..
More news
Financials ($)
Sales 2019 7 682 M
EBIT 2019 1 227 M
Net income 2019 755 M
Debt 2019 3 467 M
Yield 2019 2,43%
P/E ratio 2019 15,31
P/E ratio 2020 14,20
EV / Sales 2019 1,95x
EV / Sales 2020 1,89x
Capitalization 11 540 M
Duration : Period :
Quest Diagnostics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUEST DIAGNOSTICS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 21
Average target price 94,7 $
Spread / Average Target 10%
EPS Revisions
Stephen H. Rusckowski Chairman, President & Chief Executive Officer
Mark J. Guinan Chief Financial Officer & Executive Vice President
Lidia L. Fonseca Chief Information Officer & Senior Vice President
Jay G. Wohlgemuth Chief Medical Officer, Senior VP-R&D, Medical
Gail R. Wilensky Independent Director
Sector and Competitors